DRTECH (214680) Fundamentals 2026 — Revenue Analysis | SniperIQ
DRTECH (214680) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩77.6B, trading at ₩930.00 on the KOE. This SniperIQ fundamentals page covers DRTECH's valuation, profitability (net margin -16.7%), revenue (₩116.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is DRTECH's market cap?
DRTECH (214680) has a market capitalization of approximately ₩77.6B, trading at ₩930.00 on the KOE. Market cap moves with the live share price.
What is DRTECH's P/E ratio?
DRTECH's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is DRTECH?
DRTECH runs a net profit margin of -16.7%, a gross margin of 37.3%, and an operating margin of -8.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does DRTECH generate?
DRTECH reported revenue of ₩116.3B for fiscal year 2025, with net income of -₩24.0B and earnings per share (EPS) of -321.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does DRTECH pay a dividend?
DRTECH does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is DRTECH financially healthy?
DRTECH carries a debt-to-equity ratio of 1.17x and a current ratio of 1.70x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is DRTECH a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For DRTECH (214680) the key facts are: market cap ₩77.6B, revenue ₩116.3B, 52-week range 850-2365. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track DRTECH's full fundamentals live
Get DRTECH's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.